Skip to content
RDL Network logo
Rationale, design, and results from RENO-DEFEND 1: A randomized, dose-finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure — Peter S. Pang (2011) | RDL Network